zardaverine has been researched along with Lung Diseases, Obstructive in 1 studies
zardaverine: structure given in first source
zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
Excerpt | Relevance | Reference |
---|---|---|
"Zardaverine is a selective inhibitor of phosphodiesterase (PDE) III and IV isozymes." | 2.68 | Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. ( Reiber, C; Rentz, K; Sybrecht, GW; Ukena, D, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ukena, D | 1 |
Rentz, K | 1 |
Reiber, C | 1 |
Sybrecht, GW | 1 |
1 trial available for zardaverine and Lung Diseases, Obstructive
Article | Year |
---|---|
Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction.
Topics: Aged; Albuterol; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Humans; Lung | 1995 |